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OBJECTIVE — To investigate the association of type 2 diabetes with subcortical infarctions.
RESEARCH DESIGN AND METHODS — We investigated this association in subjects
with type 2 diabetes (case subjects; n  93) and without type 2 diabetes (control subjects; n 
186), matched by age, sex, and years of education. Participants were a subset of the Mayo Clinic
Study of Aging (median age 79 years) who had undergone magnetic resonance imaging.
RESULTS — The frequency of subcortical infarctions was 39% in case subjects and 29% in
control subjects (odds ratio 1.59 [95% CI 0.91–2.75]). The association was stronger in case
subjects without treatment (2.60 [1.11–6.08]) and in case subjects with diabetes-related com-
plications (1.96 [1.02–3.74]) compared with control subjects.
CONCLUSIONS — These ﬁndings suggest that untreated type 2 diabetes and type 2 diabe-
tes with complications are associated with subcortical infarctions.
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T
ype 2 diabetes is associated with an
increasedriskofstroke(1),silentin-
farctions (2), cognitive impairment
(3,4), and dementia (5). Few studies have
examined the associations with magnetic
resonance imaging (MRI) measures of ce-
rebrovascular disease among individuals
randomly selected from the population
(2,6). The objective of our study was to
investigate the association of type 2 dia-
betes with subcortical infarctions.
RESEARCH DESIGN AND
METHODS— The study design and
methodology are published (7). Brieﬂy,
Mayo Clinic Study of Aging participants
were Olmsted County residents aged
70–89 years on 1 October 2004, who
were randomly selected from the popula-
tion to investigate risk factors for mild
cognitive impairment (MCI) and demen-
tia. In a subset of 432 study participants
who had undergone imaging, we
matched 93 individuals with type 2 dia-
betes by age, sex, and years of education
to 186 control subjects without type 2 di-
abetes.Studyprotocolswereapprovedby
the Mayo Clinic and Olmsted Medical
Center Institutional Review Boards.
Criteria for type 2 diabetes were 1)
treatment (oral antidiabetic agents, insu-
lin) or 2) fasting blood glucose 126
mg/dl on two separate occasions or 3)a
physician diagnosis, using information
from participant medication bottles and
from the participant medical record (3).
Individuals who only met the latter two
criteria were considered as having type 2
diabeteswithouttreatment;theyhadvery
mild disease (median glycosylated hemo-
globin [HbA1c] was 5.8% [range 5.1–
6.7%]). Diabetes-related complications
were deﬁned as self-reported physician-
diagnoseddiabeticnephropathy,retinop-
athy, or neuropathy (3).
Demographic factors were assessed
by interview, and vascular risk factors
(hypertension, coronary heart disease,
and dyslipidemia) were assessed from the
medical record. Height and weight were
measured, and apolipoprotein (apoE) ε 4
genotypingwasperformed.Cognitivesta-
tus was evaluated by a nurse, a neurolo-
gist, and by cognitive testing for a
diagnosis of cognitively normal, MCI, or
dementia as previously described (7).
Acquisition of MRI
MRIstudieswereperformedona3-Tsys-
tem (Signa; GE Healthcare, Waukesha,
WI), with an eight-channel phased-array
headcoilandaﬂuid-attenuatedinversion
recovery sequence (8). A trained techni-
cianassessedpresenceofwhitematterhy-
perintensities (WMHs), hemispheric
cortical infarctions (10 mm), and sub-
cortical infarctions (lacunar infarctions in
the central gray or capsular region or in
the hemispheric white matter; areas 3
mm, dark in the center, bright rim, and
not a perivascular space) as previously
described (9).
Statistical analyses
We compared subcortical infarctions
(present or absent) in case subjects and
control subjects using logistic regression
methods with adjustment for age, sex,
yearsofeducation,andapoEε 4allelecar-
rier status (model 1) and with additional
adjustment for potential confounders or
covariates (model 2).
RESULTS— Consistent with the
matched case-control design, the distri-
butions of age (median 79 years), sex
(41%female),yearsofeducation(median
12years),andapoEε 4allelecarrierstatus
(26%) were similar in case subjects and
control subjects. Case subjects (vs. con-
trol subjects) had a higher frequency of
hypertension(94vs.68%;P0.01),BMI
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2 (33 vs. 21%; P  0.03), cor-
onary heart disease (40 vs. 27%; P 
0.04), dyslipidemia (88 vs. 70%; P 
0.001), and median HbA1c levels (6.0
vs. 5.0%; P  0.01) but did not differ
from control subjects in the frequency of
smoking(57vs.56%;P0.86),MCI(25
vs. 22%; P  0.49), or WMH (15 vs. 16
cm
3; P  0.86).
Of the 90 subjects with subcortical
infarctions, 55 subjects had one, 20 had
two, and 5 had three to nine subcortical
infarctions detected. The frequency of
subcortical infarctions was higher in case
subjects (39%) than in control subjects
(29%; odds ratio [OR] 1.59 [95% CI
0.91–2.75]; P  0.10). Compared with
control subjects, the OR was elevated for
case subjects without treatment for type 2
diabetes, case subjects with diabetes-
related complications, and case subjects
diagnosed with type 2 diabetes in late life
(Table 1). Hypertension was not associ-
ated with subcortical infarctions, and
there was no interaction of hypertension
with type 2 diabetes.
Whenrestrictedtocasesubjectsonly,
the OR of subcortical infarctions was ele-
vated in case subjects without treatment
(OR 2.34 [95% CI 0.84–6.54]; P 
0.10), case subjects treated with insulin
(1.51 [0.43–5.26]; P  0.52) compared
withcasesubjectstreatedwithoralantidi-
abetic agents (reference group), case sub-
jects with complications versus no
complications (1.75 [0.61–5.05]; P 
0.30),casesubjectswithdiagnosisataged
65 years versus aged 65 years (1.75
[0.61–5.05]; P  30), and case subjects
with shorter versus longer duration of di-
abetes (2.61 [1.01–6.75]; P  0.05).
CONCLUSIONS — In this elderly
sample,subjectswithuntreatedtype2di-
abetes, diabetes-related complications,
andlaterageatdiagnosisweremorelikely
tohavesubcorticalinfarctions.Treatment
with insulin was associated with an ele-
vated OR. Untreated type 2 diabetes may
contribute to subclinical microvascular
disease and undetected large vessel ath-
erosclerotic disease (10). In a stroke reg-
istry, type 2 diabetes was associated with
multiple lacunar infarctions (11). Insulin
treatment, a marker for disease severity,
hasbeenassociatedwithmicro-andmac-
rocerebrovascular disease including sub-
cortical infarctions (12). The present
ﬁndings are consistent with a role of sub-
cortical infarctions as a mediator of cog-
nitive impairment in patients with type 2
diabetes. The nonsigniﬁcant association
for insulin-treated diabetes may be due to
survival bias and underrepresentation of
subjects with insulin-treated diabetes in
our study, given the increased risk of
mortality and stroke in subjects with se-
vere diabetes or to limited power due to
small numbers.
Consistent with our study, type 2 di-
abetes was associated with an increased
risk of lacunar infarctions in the Honolu-
lu-Asia Aging Study (6), the Utrecht Dia-
beticEncephalopathyStudy(13),andthe
CardiovascularHealthStudy(14).Incon-
trast, others have not found associations
oftype2diabeteswithlacunarinfarctions
(15) or have observed associations with
WMH (13).
Potential limitations of our study in-
cludethecross-sectionaldesign,potential
nonparticipation bias, underrepresenta-
tion of subjects with early onset of diabe-
tes, and inadequate power to assess
associations of type 2 diabetes with corti-
cal infarctions.
Insummary,ourﬁndingssuggestthat
untreated type 2 diabetes, diabetes-
related complications, and insulin treat-
ment are associated with subcortical
infarctions.
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Table 1—Association of type 2 diabetes and diabetes-related measures with subcortical
infarctions*
Parameter n
Subcortical infarctions
Model 1 Model 2
OR (95% CI)
P
value OR (95% CI)
P
value
Treatment
No type 2 diabetes 186 1.00 (reference) — 1.00 (reference) —
With treatment 65 1.27 (0.67–2.39) 0.47 1.38 (0.70–2.73) 0.35
Without treatment 28 2.60 (1.11–6.08) 0.03 2.70 (1.11–6.55) 0.03
Type of type 2 diabetes treatment
No type 2 diabetes 186 1.00 (reference) — 1.00 (reference) —
With oral treatment 46 1.13 (0.55–2.32) 0.73 1.25 (0.58–2.69) 0.56
With insulin treatment 19 1.72 (0.58–5.03) 0.33 1.78 (0.59–5.52) 0.30
Without treatment 28 2.60 (1.11–6.10) 0.03 2.72 (1.12–6.61) 0.03
Type 2 diabetes-related
complications
No type 2 diabetes 186 1.00 (reference) — 1.00 (reference) —
No complications 37 1.12 (0.50–2.52) 0.78 1.26 (0.54–2.94) 0.59
With complications 56 1.96 (1.02–3.74) 0.04 2.10 (1.04–4.23) 0.04
Age at diagnosis of type 2
diabetes (years)
No type 2 diabetes 186 1.00 (reference) — 1.00 (reference) —
Aged 65 years 28 1.06 (0.41–2.74) 0.91 1.20 (0.45–3.22) 0.72
Aged 65 years 65 1.84 (1.00–3.38) 0.05 1.95 (1.01–3.73) 0.05
Duration of type 2 diabetes
No type 2 diabetes 186 1.00 (reference) — 1.00 (reference) —
8 years 46 0.97 (0.46–2.07) 0.95 1.00 (0.44–2.24) 1.00
8 years 47 2.44 (1.22–4.87) 0.01 2.67 (1.29–5.53) 0.01
*Case subjects were matched to control subjects without type 2 diabetes by age, sex, and years of education.
Model 1 includes adjustment for age, sex, years of education (as a continuous variable), and apoE ε 4 allele
carrier status to account for any residual confounding. Model 2 includes model 1 variables in addition to
hypertension, dyslipidemia, coronary heart disease, BMI, and smoking. When we examined associations
with subcortical infarctions as an ordinal variable (0, 1, and 2), the magnitude of the associations were
attenuated but remained in the same direction as in the table. With subjects without type 2 diabetes as the
references groups, the estimates for model 1 are as follows: oral antidiabetic agents (OR 1.03 95% CI
0.51–2.08;P0.93),insulinuse(1.640.58–4.61;P0.35);withouttreatment(2.030.91–4.53;P
0.08); without diabetes-related complications (1.03 0.47–2.27; P  0.95) and with complications (1.68
0.90–3.13; P  0.10); age at diagnosis 65 years (1.10 0.44–2.75; P  0.84) and 65 years (1.52
0.84–2.74; P  0.16); short duration of diabetes (0.93 0.45–1.94; P  0.86); 8 years (1.94 1.00–
3.74; P  0.05).
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